journal article·2026-01-05

Platelet Glycoprotein VI Inhabitable MXene-Incorporated Fibrous Scaffolds for Preventing Tumor Progression and Metastasis

Wei Yang, Debao Shi, Lianzi Wang, Min Zhang, Liying Lv, Jinglin Wang, Xiaoya Ding

ACS Materials Letters· Volume 8· Issue 1
Publisher page

Abstract

Postoperative recurrence and metastasis remain major causes of mortality in breast cancer due to residual tumor cells and complex metastatic processes. Here, we develop an NIR-responsive MXene-based scaffold that integrates antiplatelet therapy, chemotherapy, and photothermal therapy for postoperative intervention. The scaffold is fabricated by printing sodium alginate, gelatin methacryloyl, and MXene into CaCl 2 solution followed by UV cross-linking. Benefiting from the photothermal capacity of MXene nanosheets, the scaffold enables efficient photothermal conversion and NIR-triggered drug release. Incorporation of the platelet glycoprotein (GPVI) inhibitor evobrutinib disrupts platelet–tumor interactions, thereby suppressing epithelial–mesenchymal transition and tumor invasion. In vivo, the scaffold provides sustained doxorubicin release and photothermal ablation to inhibit residual tumor growth while reducing lung metastasis through GPVI blockade. Transcriptomic analysis further confirms that the scaffold impedes tumor progression by modulating platelet activation and angiogenesis. This multifunctional platform offers a promising strategy for preventing postoperative breast cancer recurrence and metastasis.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · MXene and MAX Phase Materials · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Clinical Laboratory

The First Affiliated Hospital of Anhui Medical University

Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School

Nanjing University

MOE Innovation Center for Basic Research in Tumor Immunotherapy, Anhui Province Key Laboratory of Tumor Immune Microenvironment and Immunotherapy

Funding

National Natural Science Foundation of China

References (48)

Show source-provided references
1. 10.6004/jnccn.2024.003510.6004/jnccn.2024.0035 ↗
2. 10.1016/j.cell.2023.01.04010.1016/j.cell.2023.01.040 ↗
3. 10.1093/annonc/mdy272.34810.1093/annonc/mdy272.348 ↗
4. 10.1016/j.biomaterials.2020.12022410.1016/j.biomaterials.2020.120224 ↗
5. 10.1016/j.cell.2019.10.02410.1016/j.cell.2019.10.024 ↗
6. 10.1016/S1470-2045(09)70031-210.1016/S1470-2045(09)70031-2 ↗
7. 10.1038/s41571-020-0410-210.1038/s41571-020-0410-2 ↗
8. 10.1038/s41467-022-30306-710.1038/s41467-022-30306-7 ↗
9. 10.1002/smll.20230989410.1002/smll.202309894 ↗
10. 10.1186/s12951-022-01270-710.1186/s12951-022-01270-7 ↗
11. 10.1021/acs.nanolett.2c0090710.1021/acs.nanolett.2c00907 ↗
12. 10.1016/j.actbio.2022.10.03110.1016/j.actbio.2022.10.031 ↗
13. 10.1186/s12951-024-02416-510.1186/s12951-024-02416-5 ↗
14. 10.1182/blood-2017-05-74318710.1182/blood-2017-05-743187 ↗
15. 10.1186/s13045-018-0669-210.1186/s13045-018-0669-2 ↗
16. 10.1002/smtd.20230100210.1002/smtd.202301002 ↗
17. 10.1016/j.scib.2017.09.00610.1016/j.scib.2017.09.006 ↗
18. 10.1002/SMMD.2022001910.1002/SMMD.20220019 ↗
19. 10.1038/s44286-023-00001-510.1038/s44286-023-00001-5 ↗
20. 10.1002/SMMD.6610.1002/SMMD.66 ↗
21. 10.1002/adma.20231248810.1002/adma.202312488 ↗
22. 10.31635/ccschem.024.20230379310.31635/ccschem.024.202303793 ↗
23. 10.1016/j.biomaterials.2024.12287010.1016/j.biomaterials.2024.122870 ↗
24. 10.1158/2159-8290.CD-12-032910.1158/2159-8290.CD-12-0329 ↗
25. 10.1158/1078-0432.CCR-16-327210.1158/1078-0432.CCR-16-3272 ↗
26. 10.1186/s13046-024-03001-210.1186/s13046-024-03001-2 ↗
27. 10.1016/j.pharmthera.2020.10763010.1016/j.pharmthera.2020.107630 ↗
28. 10.1182/blood.201900264910.1182/blood.2019002649 ↗
29. 10.1182/blood.201887704310.1182/blood.2018877043 ↗
30. 10.1182/bloodadvances.201900061710.1182/bloodadvances.2019000617 ↗
31. 10.1055/s-0039-167774410.1055/s-0039-1677744 ↗
32. 10.1002/smll.20220524910.1002/smll.202205249 ↗
33. 10.1002/adhm.20220220810.1002/adhm.202202208 ↗
34. 10.1038/s41467-019-12313-310.1038/s41467-019-12313-3 ↗
35. 10.1038/s41467-017-00411-z10.1038/s41467-017-00411-z ↗
36. 10.1038/s41584-019-0324-510.1038/s41584-019-0324-5 ↗
37. 10.1186/s12964-023-01066-810.1186/s12964-023-01066-8 ↗
38. 10.1038/s41586-019-1897-510.1038/s41586-019-1897-5 ↗
39. 10.1182/blood-2017-01-76104910.1182/blood-2017-01-761049 ↗
40. 10.1016/j.ccell.2019.01.00710.1016/j.ccell.2019.01.007 ↗
41. 10.3390/cells810111810.3390/cells8101118 ↗
42. 10.3389/fcell.2021.58357210.3389/fcell.2021.583572 ↗
43. 10.1016/j.ccr.2011.09.00910.1016/j.ccr.2011.09.009 ↗
44. 10.1016/j.cell.2016.11.03710.1016/j.cell.2016.11.037 ↗
45. 10.1002/advs.20220115510.1002/advs.202201155 ↗
46. 10.1161/CIRCRESAHA.115.30630110.1161/CIRCRESAHA.115.306301 ↗
47. 10.1111/jth.1584410.1111/jth.15844 ↗
48. 10.3390/cells1122370410.3390/cells11223704 ↗